知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.031 seconds)

    STEM CELL MICROPARTICLES
    1.
    发明申请
    STEM CELL MICROPARTICLES 审中-公开
    干细胞微核

    公开(公告)号：US20150164955A1

    公开(公告)日：2015-06-18

    申请号：US14414670

    申请日：2013-07-18

    Applicant: RENEURON LIMITED

    Inventor： John Sinden ,  Lara Stevanato ,  Randolph Corteling

    IPC: A61K35/30 ,  C12N5/0797 ,  A61K9/16

    CPC classification number: A61K35/30 ,  A61K9/1664 ,  A61K31/7105 ,  A61K31/713 ,  C12N5/0623 ,  C12N2501/15 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/999

    Abstract: This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).

    Abstract translation: 本发明涉及干细胞微粒，其用途和生产，特别是神经干细胞微粒及其在治疗中的应用。 干细胞微粒通常是外来体或微泡，并且可以衍生自神经干细胞系。 神经干细胞系可以是有条件永生化的干细胞系，例如CTX0E03（保藏在ECACC，登录号04091601）。

    INDUCED PLURIPOTENT CELL COMPRISING A CONTROLLABLE TRANSGENE FOR CONDITIONAL IMMORTALIZATION
    4.
    发明申请
    INDUCED PLURIPOTENT CELL COMPRISING A CONTROLLABLE TRANSGENE FOR CONDITIONAL IMMORTALIZATION 有权

    公开(公告)号：US20210371828A1

    公开(公告)日：2021-12-02

    申请号：US17284428

    申请日：2019-10-11

    Applicant: ReNeuron Limited

    Inventor： Steve PELLS ,  Randolph CORTELING ,  John Sinden

    IPC: C12N5/074 ,  A61K35/545

    Abstract: The invention relates to induced pluripotent stem cells that are generated from cells, for example Adult Stem Cells, that are conditionally-immortalisable. In particular, the invention relates to induced pluripotent stem cells generated from stem cell lines comprising a controllable transgene for conditional immortalisation, and the progeny of those induced pluripotent stem cells. Induced pluripotent stem cells, progeny cells derived from those pluripotent cells, compositions comprising those cells, methods of making all of those cells, and uses of all of those cells are also described.

    METHOD OF PRODUCING MICROPARTICLES
    5.
    发明申请
    METHOD OF PRODUCING MICROPARTICLES 审中-公开
    生产微生物的方法

    公开(公告)号：US20160002597A1

    公开(公告)日：2016-01-07

    申请号：US14767280

    申请日：2014-02-12

    Applicant: Reneuron Limited

    Inventor： John Sinden ,  Lara Stevanato ,  Randolph Corteling

    IPC: C12N5/0797 ,  A61K35/12

    CPC classification number: C12N5/0623 ,  A61K31/7105 ,  A61K35/12 ,  A61K35/30 ,  C12N5/0647 ,  C12N2500/90 ,  C12N2501/148 ,  C12N2501/15 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2502/088 ,  C12N2502/1171

    Abstract: The invention is based on the finding that microparticles can be produced by conditionally-immortalised cells. The conditionally-immortalised cells may be stem cells. The Examples show the successful harvest of microparticles from conditionally immortalised neural stem cells and CD34+ cells. Conditional immortalisation provides a constant supply of clonal cells that produce microparticles such as exosomes. The conditionally immortalised cells are useful as “producer cells” for microparticles such as exosomes, which are typically harvested or isolated from the conditionally-immortalised cells.

    Abstract translation: 本发明是基于通过有条件永生化细胞产生微粒的发现。 有条件永生化的细胞可以是干细胞。 实施例显示从条件永生化神经干细胞和CD34 +细胞中成功收获微粒。 条件永生化提供了产生微粒例如外来体的克隆细胞的不断供应。 有条件永生化细胞可用作微粒例如外来体的“生产细胞”，其通常从有条件永生化细胞中收获或分离。

    METHODS OF TREATING STROKE THROUGH ADMINISTRATION OF CTX0E03 CELLS
    6.
    发明申请
    METHODS OF TREATING STROKE THROUGH ADMINISTRATION OF CTX0E03 CELLS 审中-公开
    通过CTX0E03细胞管理治疗方法

    公开(公告)号：US20130045189A1

    公开(公告)日：2013-02-21

    申请号：US13660647

    申请日：2012-10-25

    Applicant: UNIVERSITY OF SOUTH FLORIDA ,  RENEURON LIMITED

    Inventor： Paul R. Sanberg ,  John Sinden

    IPC: A61K35/30 ,  A61P25/00 ,  A61P25/28

    CPC classification number: C12N5/0623 ,  A61K35/12

    Abstract: The subject invention pertains to methods to enhance the therapeutic effects of cellular or drug treatment in various diseases and disorders. More particularly, the present invention provides methods of treating disorders by administering CTX0E03 cells to the patient, intravenously or intraarterially. The treatment is useful for neurodegenerative diseases, such as stroke. The CTX0E03 cells may be cryopreserved and/or passaged before administration into the patient. Administration of the CTX0E03 cells into stroke rat models was at or within 48 hours after stroke. Testing of the rat models through elevated body swing test to measure of neurobehavioral status at the time of transplant and repeated triphenyltetrazolium chloride (TTC) staining as a measure of infarct volume showed short term survival that provided significant protection from the stroke.

    Abstract translation: 本发明涉及增强细胞或药物治疗在各种疾病和病症中的治疗效果的方法。 更具体地，本发明提供了通过向患者静脉内或动脉内施用CTX0E03细胞来治疗疾病的方法。 治疗对于神经变性疾病如中风是有用的。 CTX0E03细胞可以在给予患者之前被冷冻保存和/或传代。 CTX0E03细胞进入中风大鼠模型是在中风后48小时内或之后。 通过升高的身体摆动测试来测试大鼠模型，以测量移植时的神经行为状态，并重复三苯基四氮唑（TTC）染色作为梗塞体积的量度，显示短期存活提供了显着的中风保护。

    Stem cell microparticles and miRNA
    7.
    发明授权
    Stem cell microparticles and miRNA 有权

    公开(公告)号：US10406182B2

    公开(公告)日：2019-09-10

    申请号：US15027424

    申请日：2014-10-09

    Applicant: RENEURON LIMITED

    Inventor： Caroline Hicks ,  John Sinden ,  Lara Stevanato ,  Randolph Corteling

    IPC: C12N15/113 ,  A61K35/30 ,  C12N5/0797 ,  A61K9/00

    Abstract: This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalized stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).

    STEM CELL MICROPARTICLES AND miRNA
    8.
    发明申请
    STEM CELL MICROPARTICLES AND miRNA 审中-公开
    干细胞微核和miRNA

    公开(公告)号：US20160235788A1

    公开(公告)日：2016-08-18

    申请号：US15027424

    申请日：2014-10-09

    Applicant: RENEURON LIMITED

    Inventor： Caroline Hicks ,  John Sinden ,  Lara Stevanato ,  Randolph Corteling

    IPC: A61K35/30 ,  C12N5/0797 ,  C12N15/113

    CPC classification number: A61K35/30 ,  A61K9/0019 ,  C12N5/0623 ,  C12N15/113 ,  C12N2310/141 ,  C12N2501/15 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2502/088

    Abstract: This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).

    Abstract translation: 本发明涉及从这些微粒分离的干细胞微粒和miRNA，其使用和生产，特别是神经干细胞微粒及其在癌症治疗中的用途，通常是巢蛋白阳性癌症。 癌症可能是胶质瘤，黑素瘤，乳腺癌，胰腺癌或前列腺癌。 干细胞微粒通常是外来体或微泡，并且可以衍生自神经干细胞系。 神经干细胞系可以是有条件永生化的干细胞系，例如CTX0E03（保藏在ECACC，登录号04091601）。

    STEM CELL MICROPARTICLES
    10.
    发明申请
    STEM CELL MICROPARTICLES 审中-公开

    公开(公告)号：US20190388475A1

    公开(公告)日：2019-12-26

    申请号：US16554388

    申请日：2019-08-28

    Applicant: Reneuron Limited

    Inventor： John Sinden ,  Lara Stevanato ,  Randolph Corteling

    IPC: A61K35/30 ,  G01N33/50 ,  C12N15/113

    Abstract: This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTXOE03 (deposited at the ECACC with Accession No. 04091601).

Patent Agency Ranking